Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Expert Opin Investig Drugs. 2010 Oct;19(10):1161-78. doi: 10.1517/13543784.2010.513380.
Irritable bowel syndrome (IBS) is a common disorder with significant health and economic consequences. The etiology of IBS is complex and appears to be multifactorial. Traditional IBS therapies have been directed primarily at the relief of individual symptoms but have been largely disappointing. This has triggered the search for newer treatment strategies with improved patient outcomes.
Enhanced knowledge about the putative pathophysiology of IBS has allowed the identification of new mechanistic targets for treatment. Our aim is to review emerging and promising drugs in the treatment of IBS based on disease pathophysiology. Data were extracted using Medline and PubMed search engines until January 2010. Abstracts were identified through 'Web of Science' and abstract supplements of major gastrointestinal scientific meetings. Drugs were classified according to mechanism of action and those with efficacy in trials involving human subjects examined.
Additional insight into the pathophysiology as well as current and prospective treatments of IBS.
A multitude of putative drug targets have been identified and some novel treatments have progressed through to human clinical trials, but very few will be approved for the market in the near future. Moreover, and in keeping with the complex and multifactorial nature of this syndrome, it is unlikely that there will be one dominant and universally effective form of therapy for all IBS patients.
肠易激综合征（IBS）是一种常见的疾病，具有显著的健康和经济后果。IBS 的病因复杂，似乎是多因素的。传统的 IBS 治疗主要针对缓解个别症状，但效果大多不尽如人意。这引发了对新的治疗策略的探索，以改善患者的结局。
对 IBS 假定病理生理学的深入了解，使得能够确定新的治疗机制靶点。我们的目的是根据疾病病理生理学，综述治疗 IBS 的新兴和有前途的药物。使用 Medline 和 PubMed 搜索引擎检索数据，直到 2010 年 1 月。通过“Web of Science”和主要胃肠科学会议的摘要补充来确定摘要。根据作用机制对药物进行分类，并对涉及人体受试者的试验中具有疗效的药物进行检查。
对 IBS 的病理生理学以及当前和潜在治疗方法的更多了解。
已经确定了许多假定的药物靶点，一些新的治疗方法已经进入人体临床试验，但在不久的将来，很少有药物会获得市场批准。此外，鉴于这种综合征的复杂性和多因素性质，不太可能有一种主要的、普遍有效的治疗方法适用于所有 IBS 患者。
